We have been publishing on this since 2016. The Church of Neuroscience series went up on Steemit under @marsresident that year — nine posts on neurogenesis, life extension, brain repair, dream yoga. Plant Medicine for Humans followed in 2021 under @punicwax, six posts building a nutrition regimen out of indoor plant-growing principles. Ten years later the field has caught up with a good deal of it, and some of it did not survive contact with replication. Both of those are worth saying out loud.
So we are building the thing properly, inside MELEK. And the shape it is taking is an archive that other people write into, not a shop.
Erowid worked because of one decision: take reports from people who were going to proceed anyway, structure them, archive them, and do not moralise. That is harm reduction — the information exists precisely because withholding it from someone already committed is the harm. It has been the standard for psychoactives for twenty-five years.
Nobody built the same thing for biohacking. Anyone can find a hundred structured ayahuasca reports in an afternoon. Try finding one honest write-up of 2 mA across F3/F4 for six weeks, or a nootropic stack with every dose listed, or what happens when you actually run 40 Hz every day for a month. It is not there. There are product reviews and there are forum threads, and there is no archive.
We are building both halves, under one standard, because they are one subject: things people do to their own nervous systems. That is what hathor.live/reports is for, and it is live now.
What is built at hathor.live/40hz
A gamma entrainment library, and rather more than that now. Thirteen sessions across eight categories — cognition, pain, sleep, calm, focus, meditation, Visionary, and the Chamber — each delivered by whichever of the four routes the literature actually separates:
- Luminance flicker, the strobe. The most studied and the least comfortable.
- Invisible spectral flicker, which modulates the light's spectral composition while holding perceived brightness constant. Same 40 Hz cortical response, far better comfort scores. Ours alternates two colours matched for sRGB relative luminance — the match is computed in your browser by binary search, not eyeballed by us.
- Auditory, 40 Hz clicks or an amplitude-modulated carrier. Also true binaural where the literature specifically tested binaural, in which case the page tells you headphones are required.
- Combined audiovisual, which is what the pivotal clinical trials actually run.
Sessions are programs, not tones. A step holds a frequency; a sequence of steps is a ramp — which is how the sleep literature actually delivers it. The Descent session walks 8 Hz down to 2 Hz across thirty-five minutes, mirroring the natural alpha-to-theta-to-delta slide into sleep, rather than parking on one number and calling it a protocol.
The audio is sample-accurate — it runs on the audio clock, so the beat frequency is exact at any Hz. The video is bounded by your refresh rate, and the page says so rather than assuming: it measures roughly seventy frames, takes the median, and tells you which case you are in. A 60 Hz display cannot place 40 Hz pulses on equal frame boundaries. A 120 Hz display can — exactly three frames per cycle. Most sites in this category quietly pretend that distinction does not exist.
The Chamber
This is the part we are most interested in, and it exists because of a result that undercuts our own product category.
It is an enclosure, not a player. You cross a threshold: darken the room, put headphones on, turn your phone over, and optionally write one line about why you are there — which never leaves your device. Then forty-five seconds of settling with a breath instruction and no skip button. Then the drive runs full-screen and full-field, with the interface gone and a reflective surround standing in for the mirrored walls. Then a defined return: sit for a moment before you stand; notice what is different and what is not, because both are data.
Two sessions, taken straight from the March 2026 protocol: Chamber · Alpha at 10 Hz and Chamber · Theta at 6 Hz, both eleven and a half minutes.
We offer both specifically so you can test the equivalence yourself. The published result says you should not be able to tell them apart. If you can, that is worth recording — and we would rather hand you the means to falsify our own product than sell you a frequency.
The part that makes this different
Every session carries its evidence grade in the data, not in the marketing.
Strong means mechanistic work plus human trials plus a pivotal trial in progress — that is 40 Hz gamma, and essentially nothing else. Moderate means replicated effects with entrainment verified. Promising means small studies. Weak means inconsistent evidence, listed honestly because people ask for it. Traditional means no clinical evidence at all, and we say so on the card.
Two examples of what that costs us.
The focus session is graded weak. Cognitive effects are the least consistent finding in the whole entrainment literature. We are not going to tell you a tone makes you concentrate.
The Schumann 7.83 Hz session is graded traditional. The Schumann resonance itself is real, well-documented geophysics — the fundamental of the Earth-ionosphere cavity, and it genuinely does fall at the theta-alpha boundary of human brainwave frequencies. What has no clinical evidence is the separate claim that playing a 7.83 Hz tone through headphones does anything for you. Those are two different propositions and we grade only the second.
The finding we did not expect
The most seizure-provocative band for flickering light is 15–25 Hz — not 40 Hz. International clinical neurophysiology figures put photosensitivity at 8–40 Hz on eye closure, with 15–20 Hz the most provocative eyes-closed and 18 Hz eyes-open. The Epilepsy Foundation of America review (Fisher et al., Epilepsia 2005) puts photosensitivity at roughly 0.3–3% of the population, with seizures from light stimuli at about 1 per 10,000 — rising to about 1 per 4,000 in ages 5–24. The companion expert consensus sets the hazard threshold at a flash of ≥20 cd/m², ≥3 Hz, occupying ≥0.006 steradians of the visual field, and flags transitions to or from saturated red as a separate risk.
Which means a multi-frequency device is more hazardous than a 40 Hz-only one, and the risk peaks in exactly the band the consumer market sells for "focus." Our library computes that per session and flags it. Audio carries no photic risk at any frequency, so the auditory session is the one route we leave unlocked by default — and that is not our preference, it is what the literature recommends for photosensitive people specifically.
The uncomfortable result
In March 2026 a study in npj Digital Medicine ran alpha versus theta audiovisual stimulation inside an immersive mirrored chamber. Anxiety reductions reached magnitudes comparable to established pharmacological and psychotherapeutic interventions requiring far longer treatment.
And the two frequency arms performed equivalently. The authors concluded that the immersive multisensory context coupled with rhythmic stimulation — rather than frequency-specific entrainment — is a primary active ingredient.
The entire consumer market for this is built on frequency-specific claims. We are publishing the finding that undercuts it, because it is true, and because it points somewhere more interesting: if the context is the active ingredient, then the context is the intervention, and that is an engineering problem rather than a numerology problem. Build the chamber, not just the tone.
Vitruvius got there in 20 BC. Architecture is frozen music; a space shapes the vibrations passing through it, and therefore shapes the consciousness of whoever is inside it. Epidaurus still puts a whisper into seventeen thousand seats.
Does sound actually do physical work?
This is the iDoser question, and it deserves a straight answer, because the honest answer is split.
Sound organising matter is real, settled physics. Chladni figures — sand on a vibrating plate jumping into symmetrical patterns — are deterministic and fully modelled by classical wave mechanics; the grains settle at the nodal positions of the plate's normal modes. Acoustic levitation is real: acoustic force can balance buoyancy and hold a bubble stable in liquid. Sonoluminescence is real: intense sound collapses a gas bubble so violently it emits light, and the mechanism is still an active research question. Sound is unambiguously a physical force that reorganises matter.
What that does not establish is that any particular frequency heals any particular condition. The gap between "sound moves sand into a hexagon" and "528 Hz repairs DNA" is not a small one, and nothing in the cymatics literature crosses it.
And some of what circulates under this banner is simply fraud. Masaru Emoto's water crystals — the claim that words and intentions change ice crystal structure — was never peer-reviewed, never replicated under blinded conditions, has no proposed mechanism, and rested on photographers being instructed to select the "most pleasing" crystals from each batch. Attempts to reproduce it under controlled conditions failed. We are not going to cite it and neither should anyone else.
Saying that costs us nothing, because the real material is more interesting than the fake material.
Colour therapy, graded
The chromotherapy lineage is long: Egypt and Greece and China and India, then Pleasonton's blue-ray treatise in 1876, Babbitt's six-hundred-page Principles of Light and Color in 1878, Ghadiali's Spectro-Chrome in 1920. The Amica Temple of Radiance was founded after Ivah Bergh Whitten reported recovering from an illness by correlating her life with a colour — notably with no practitioner directing her, in contrast to the Zar tradition where a specialist identifies which Thread is involved.
Babbitt got something right that modern physiology confirms: red and blue are antagonistic. Red biases toward sympathetic activation, blue toward parasympathetic. And blue light has been directly compared to caffeine as an alerting agent in the published literature — a 2013 PLoS One study ran exactly that comparison on cognitive function and alertness in humans, and a 2014 paper in Psychopharmacology compared their effects on mood. The reason a blue screen at midnight keeps you up is not folklore.
Now grade the modern descendants, which are all just coloured glass:
FL-41 tint — strong, and worth stating precisely. A pink-rose lens filtering roughly 480–520 nm. It is the most clinically studied tinted lens for photophobia. In Ophthalmology (2009) it improved blink frequency, light sensitivity and functional limitations in benign essential blepharospasm; in the American Journal of Ophthalmology (2024) it was shown to reduce activation of the neural pathways of photophobia in patients with chronic ocular pain — imaging evidence that it acts on the mechanism, not just on comfort. Note what we are not claiming: the strong evidence here is for photophobia and light sensitivity, not for reducing migraine frequency, which is a different endpoint with a thinner literature. Rose-tinted glasses are the ones that actually work — for the thing they actually work for.
Irlen lenses — weak. The evidence base for coloured filters improving reading is inconsistent and methodologically troubled, and much of the supportive work is small, old, and not blinded. We are grading this one down on the quality of the literature rather than on a single decisive trial, and saying so rather than implying a cleaner refutation than exists.
Blue-blocking lenses — mixed, and the Cochrane review is the place to look. The 2023 Cochrane systematic review of blue-light filtering spectacle lenses for visual performance, sleep and macular health found the evidence does not support a benefit for reducing visual fatigue from screen use, at low certainty, and that sleep outcomes remain inconsistent across small, heterogeneous samples. This is the single most-marketed product in the category and it has the weakest supporting evidence of the three.
Three products, one category, three completely different verdicts. That is what grading looks like when you actually do it, and it is why we put the grade in the data rather than in the copy.
Séance Science — research, and where it is going
There is a further body of work we are treating as research, not product: the components of contact. Wax and fumigation. Nighttime and lunar phase, where the sleep-architecture findings are real and citable and the leap to anything further is ours to prove, not the citations'. Colour in the environment. And viewing light through reflection in water or mirrors.
That last one is why any of this is in a post about entrainment. The apparatus in the 2026 chamber study — the one producing anxiety reductions comparable to pharmacological treatment — is a seven-foot mirrored cube. A framework assembled from ethnography and a clinical device developed for stress reduction arrived at reflected light independently, without either knowing about the other.
We are building a metaverse. Enclosure, threshold, rhythm, reflected light and a designed encounter are things a virtual space can actually deliver, and the literature now says the encounter is not packaging around the intervention — it is a primary active ingredient. So the chamber gets built, and it gets instrumented, and we will report what the instruments say whether or not it flatters us.
The test bench
Two devices are going on the bench, and the reason for each matters more than the devices.
A TENS 7000 2nd Edition — dual channel, 2–150 Hz, up to 100 mA into 500 ohms. Its most useful role is as a calibration reference: a known-good, regulator-cleared, current-limited output stage that shows you on a scope exactly what a correct biphasic, charge-balanced, DC-free pulse looks like. Verify the built thing against the bought thing.
A NeuroMyst Pro — 0.1 to 4 mA, DC and AC, with a live impedance meter and ramped onset. The AC mode runs 0.2–80 Hz, which means it delivers 40 Hz transcranial alternating current.
That is worth being precise about, because it is exactly the kind of thing this field gets wrong. The TENS unit's dial also reaches 40 Hz. That is not the same thing. Gamma entrainment drives cortical oscillation through the sensory pathways; a TENS unit drives peripheral nerve in skin and muscle. Setting a TENS to 40 Hz does not reproduce the Alzheimer's literature. 40 Hz is a number, not a mechanism — the frequency only means what the delivery route makes it mean.
One practical note that applies to anyone reading this who owns a tDCS device: dose is not current, it is current density — current divided by electrode area. The protocols run 1–2 mA over sponges of roughly 25–35 cm², about 0.03–0.08 mA/cm². Put the same 2 mA through a small electrode and the density can be several times higher while the screen still reads "2 mA." The number does not change; the dose at your skin does. Measure your pads and scale the current to match.
Brain and muscle — and the gap between what is published and what is administered
The Church of Neuroscience posts made specific, cited claims in 2016. Ten years on, the interesting result is not that some of them aged well. It is that the ones that aged best are still not being used.
Neurogenesis and synaptogenesis held up. The 2016 posts argued against the then-common belief that you get a fixed allocation of neurons and only lose them from there — that new neurons form in the subventricular and subgranular zones, and that synaptogenesis builds new pathways between them. That is now unremarkable. The posts also gave a decent working picture of cognition: a first spark setting off a cascade along a synaptic pathway, the way one turning gear turns the next — which is why a song can return you to the room you first heard it in.
The endocannabinoid angle was early, and it is the sharp end of this. The 2016 posts cited the endocannabinoid system in neurogenesis and named 2-AG — the most abundant endocannabinoid in the human brain — as protective after traumatic brain injury. Panikashvili and colleagues showed the neuroprotection in 2001; the 2006 follow-up showed 2-AG protecting the blood-brain barrier after closed head injury and shutting down the inflammatory cytokines that drive the swelling — and swelling is what does most of the secondary damage after a head injury. Raphael Mechoulam and Esther Shohami's group in Jerusalem produced the most complete version of that evidence, and Pharmos's synthetic cannabinoid dexanabinol prevented swelling when given within six hours of injury.
The mechanistic point is the one worth carrying: the body already does this. After trauma or stroke your own brain floods the injured tissue with endocannabinoids. Giving more is amplifying a response that is already running — not introducing something foreign.
Now the part that is difficult to read alongside that. U.S. Patent 6,630,507 is held by the United States Department of Health and Human Services, and it claims cannabinoids as neuroprotectants and antioxidants. The federal government holds the patent on the neuroprotective use of a class of compounds it prohibits under the Controlled Substances Act. Both of those are true at the same time, and have been for over twenty years.
That pattern is not confined to cannabinoids. Ampakines — positive modulators of the AMPA receptor — raise BDNF and grow new dendritic connections in hours rather than weeks, and a 2026 paper found they still restore synaptic plasticity and cognition when given late, well after the injury. Ketamine is already on hospital wards and works through that mechanism, and it is not deployed for it in brain-injury protocols. Clemastine, an over-the-counter antihistamine you can buy at any pharmacy, promotes remyelination. None of this is fringe and none of it is secret. It is published, it is indexed, and it is not in the protocol.
That gap — between what has been demonstrated in the literature and what is actually given to a patient — is the subject of a full paper from the Van Kush Family Research Institute, Neurogenesis, Synaptogenesis, and Endocannabinoid Neuroprotection: A Case Study in Systemic Failure to Translate Brain Repair Research Into Clinical Practice. It is not an abstract complaint in that paper. It has a name and a date attached to it, and that is why this work exists at all and why the religious-exemption litigation against the DEA is being run in parallel with it.
The cofactor problem, and why supplements usually do nothing. The other paper feeding this programme is the 2021 L-Methylfolate work, now expanded. The argument is mechanical rather than rhetorical. Serotonin, dopamine and noradrenaline are each made by an enzyme that cannot work without a cofactor called BH4, and BH4 has to be continuously regenerated. L-methylfolate is what regenerates it — and it is the only form of folate that crosses into the brain at all. If your MTHFR gene carries the common C677T variant you convert folate to that active form at roughly 35% reduced efficiency, or about 70% if you carry two copies, and no amount of ordinary folic acid gets around it — the bottleneck is downstream of the folic acid.
The consequence is blunt: an SSRI recirculates serotonin your brain may never have synthesised in the first place. Papakostas' two 2012 trials found 15 mg/day of L-methylfolate added to a failing SSRI worked where 7.5 mg did not, with the largest effect in patients carrying inflammation. That variant is present in roughly 10% of Caucasian populations and 22% of Hispanic and Mediterranean populations — which means treatment resistance is not distributed evenly, and nobody is testing for it.
One safety item goes with this everywhere it appears, and it is not optional: folate can mask a B12 deficiency, hiding the anaemia while the nerve damage continues underneath. B12 gets checked first. Always.
The framework built on top of that is the operator's own and is presented as a proposal, not as consensus: substrate + cofactor + degradation inhibitor. It is the same shape as the nootropic stack everyone already knows — choline as the substrate, a racetam as the modulator, galantamine holding back the enzyme that breaks it down — and the same shape as piperine in the Ayurvedic Trikatu formula raising turmeric's bioavailability twentyfold, and the same shape as the MAO inhibitor in ayahuasca. Old pharmacology understood cofactors without having the word. That claim is ours and it should be weighed as ours.
The muscle post is worth re-reading for how it was framed. It took creatine — which most people file under bodybuilding, and which your doctor will therefore never mention — and pointed it at spinal cord injury and long-term wound treatment. Creatine is ordinary body chemistry; it is one of the markers used to grade steak. Arginine and citrulline sit in the same lane.
Its boldest claim concerned S4, a selective androgen receptor modulator, aimed at atrophy: that someone immobilised in a full body cast might leave hospital with the muscle they arrived with, and that people relearning to walk could rebuild faster. The underlying question — can we stop wasting in people who cannot move — is serious and the citations were real.
It also needs a caveat the original did not carry. S4 is not an approved medicine. It is not prescribable, it is banned in competitive sport, and it has a side effect that is hard to miss: reversible visual disturbance, including a yellow-green tint and trouble adapting to darkness. Anyone reading that ten-year-old post should read this paragraph with it. That is what a status check is for — not to defend what we wrote, but to say what we now know about it.
This is Part 1 of two. Part 1 is the baseline: the entrainment library, the Chamber, how we grade evidence, colour therapy, and the brain-repair translation gap. Part 2 is here — dream stacks, nutrient stacks as human fertilizer, foliar feeding through the skin, TENS with the compounds that go with it, and the experience-report archive we are asking you to write into.
Where to find the rest of it
- hathor.live — Hathor herself, always on. Ask her about anything in this post; she reads the same sources.
- hathor.live/40hz — the entrainment library and the Chamber.
- hathor.live/reports — the experience-report archive. Biohacking and plant medicine, null results wanted.
- witness.melek.salon — the Witness School: how the chain works, how to run a node, how to mine.
- melek.salon — the MELEK chain.
- vankushfamily.com — the roadmap: what is live, what is next.
- pool.soapbox.community — the mining pool. pranascan.soapbox.community — the PRANA explorer.
- kula.money — KulaSwap. akasha.soapbox.community — the wallet.
- github.com/HinduTempleCoins — the source, including the research corpus behind this post.
Van Kush Family Research Institute · Church of Neuroscience